rs782618876
|
RENBP;NAA10
|
Metabolic Syndrome X
|
|
0.010 |
GeneticVariation |
BEFREE |
To examine this, we investigated four common polymorphisms of RAGE gene: 1704G/T (rs184003), G82S (rs2070600), -374T/A (rs1800624) and -429T/C (rs1800625) in 340 obese patients with metabolic syndrome. and protein levels of AGE and RAGE.
|
29928018 |
2018 |
rs587776457
|
ARHGAP4;NAA10
|
Microphthalmia, syndromic 1
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs782618876
|
RENBP;NAA10
|
Obesity
|
|
0.010 |
GeneticVariation |
BEFREE |
The -374T/A and -429T/C did not show positive interaction with obesity and smoking status.
|
22987041 |
2012 |
rs387906701
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.840 |
GeneticVariation |
BEFREE |
Our findings expand the clinical spectrum of NAA10 and suggest that the proposed correlation between mutant Naa10 enzyme activity and phenotype severity is more complex than anticipated; the p.Tyr43Ser mutant enzyme has less catalytic activity than the p.Ser37Pro mutant associated with lethal Ogden syndrome but results in a milder phenotype.
|
26522270 |
2015 |
rs387906701
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.840 |
GeneticVariation |
BEFREE |
In conclusion, the data presented here further support the disruptive nature of the S37P/Ogden mutation and identify affected cellular processes potentially contributing to the severe phenotype seen in Ogden syndrome.
|
27668839 |
2017 |
rs387906701
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.840 |
GeneticVariation |
BEFREE |
A single hypomorphic missense variant p.(Ser37Pro) was previously associated with Ogden syndrome in eight affected males from two different families.
|
25099252 |
2015 |
rs387906701
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.840 |
GeneticVariation |
UNIPROT |
Our findings expand the clinical spectrum of NAA10 and suggest that the proposed correlation between mutant Naa10 enzyme activity and phenotype severity is more complex than anticipated; the p.Tyr43Ser mutant enzyme has less catalytic activity than the p.Ser37Pro mutant associated with lethal Ogden syndrome but results in a milder phenotype.
|
26522270 |
2015 |
rs387906701
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.840 |
GeneticVariation |
UNIPROT |
Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-acetylation defects.
|
25489052 |
2015 |
rs387906701
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.840 |
GeneticVariation |
UNIPROT |
A novel NAA10 p.(R83H) variant with impaired acetyltransferase activity identified in two boys with ID and microcephaly.
|
31174490 |
2019 |
rs387906701
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.840 |
GeneticVariation |
BEFREE |
NAA10-related syndrome is an X-linked condition with a broad spectrum of findings ranging from a severe phenotype in males with p.Ser37Pro in NAA10, originally described as Ogden syndrome, to the milder NAA10-related intellectual disability found with different variants in both males and females.
|
30054457 |
2018 |
rs387906701
|
ARHGAP4;NAA10
|
Ogden syndrome
|
G |
0.840 |
CausalMutation |
CLINVAR |
|
|
|
rs387906701
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.840 |
GeneticVariation |
UNIPROT |
Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency.
|
21700266 |
2011 |
rs863225427
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.810 |
GeneticVariation |
BEFREE |
Our findings expand the clinical spectrum of NAA10 and suggest that the proposed correlation between mutant Naa10 enzyme activity and phenotype severity is more complex than anticipated; the p.Tyr43Ser mutant enzyme has less catalytic activity than the p.Ser37Pro mutant associated with lethal Ogden syndrome but results in a milder phenotype.
|
26522270 |
2015 |
rs863225427
|
ARHGAP4;NAA10
|
Ogden syndrome
|
G |
0.810 |
CausalMutation |
CLINVAR |
|
|
|
rs863225427
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.810 |
GeneticVariation |
UNIPROT |
Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-acetylation defects.
|
25489052 |
2015 |
rs863225427
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.810 |
GeneticVariation |
UNIPROT |
Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency.
|
21700266 |
2011 |
rs863225427
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.810 |
GeneticVariation |
UNIPROT |
A novel NAA10 p.(R83H) variant with impaired acetyltransferase activity identified in two boys with ID and microcephaly.
|
31174490 |
2019 |
rs863225427
|
ARHGAP4;NAA10
|
Ogden syndrome
|
|
0.810 |
GeneticVariation |
UNIPROT |
Our findings expand the clinical spectrum of NAA10 and suggest that the proposed correlation between mutant Naa10 enzyme activity and phenotype severity is more complex than anticipated; the p.Tyr43Ser mutant enzyme has less catalytic activity than the p.Ser37Pro mutant associated with lethal Ogden syndrome but results in a milder phenotype.
|
26522270 |
2015 |
rs1057519448
|
ARHGAP4;NAA10
|
Ogden syndrome
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Lessons learned from additional research analyses of unsolved clinical exome cases.
|
28327206 |
2017 |
rs1057519448
|
ARHGAP4;NAA10
|
Ogden syndrome
|
G |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs1557107462
|
ARHGAP4;NAA10
|
Ogden syndrome
|
C |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
rs1557107528
|
ARHGAP4;NAA10
|
Ogden syndrome
|
C |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs1557107543
|
ARHGAP4;NAA10
|
Ogden syndrome
|
A |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
rs1569546255
|
ARHGAP4;NAA10
|
Ogden syndrome
|
C |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs587780562
|
ARHGAP4;NAA10
|
Ogden syndrome
|
A |
0.700 |
CausalMutation |
CLINVAR |
|
|
|